1 / 32

Histoplasmosis

Histoplasmosis. By Anastassia Doutova R2 10/06/06. Background. First described by a United States Army physician in Panama in 1906 Histoplasma capsulatum is a dimorphic fungus that remains in a mycelial form at ambient temperatures and grows as yeast at body temperature in mammals.

peers
Download Presentation

Histoplasmosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Histoplasmosis By Anastassia Doutova R2 10/06/06

  2. Background • First described by a United States Army physician in Panama in 1906 • Histoplasma capsulatum is a dimorphic fungus that remains in a mycelial form at ambient temperatures and grows as yeast at body temperature in mammals. • Endemic to the Ohio, Missouri, and Mississippi River valleys (US) and river valleys between latitudes 45° north and 30° south in North and Central America.

  3. Background Cause • Birds cannot be infected by the fungus and do not transmit the disease but their excretions enrich the growth medium for the mycelium; • bats can become infected, and transmit the fungus through droppings. • Contaminated soil can be potentially infectious for years.

  4. Background Route • inhalation of aerosolized conidia and mycelial fragments from soil results in alveolar deposition • Reactivation can occure • Reinfection is possible although controversial

  5. Epidemiology • Most prevalent endemic mycosis in US • 250-500K individuals are infected annually • 50 million people infected in US • Clinical illness occurs in <5% • in people with underlying lung disease chronic pulmonary histoplasmosis occurs at a rate of 1 per 100,000 persons per year • Clinical symptoms are more frequent in males than in females ratio of 4:1. Except for Rheumatologic manifestations which occur predominantly in females.

  6. Host Response • T lymphocytes are essential in limiting the extent of infection. • Cytokines activate macrophages for fungistatic activity against intracellular yeasts. • Organisms are confined to macrophages • Delayed-type hypersensitivity to histoplasmal antigens occurs 3-6 wk after exposure • 85-90% of immunocompetent individuals produce a positive response to skin antigen test • calcified fibrinous granulomas with areas of caseous necrosis develope over weeks to months.

  7. Course • Can take form of acute or chronic pulmonary infection but may also hematogenously spread systemically • spread may occur through the lymphatics to regional lymph nodes or the liver and spleen. • Progressive disseminated histoplasmosis is rare in adult hosts who are immunocompetent.

  8. PresentationAcute • Most individuals are asymptomatic • Those who develop clinical manifestation - usually immunocompromised - or exposed to a high quantity • onset occurs 3-14 days after exposure

  9. Acute PresentationSymptoms/findings • Common: Fever, headache, malaise, myalgia, abdominal pain, and chills, cough, hemoptysis, dyspnea, chest pain • Large innoculum: severe dyspnea • Uncomon: • Joint pain=arthritis and skin lesions=erythema multiforme, and erythema nodosum (5-6%) mostly in females. • Enlarged hilar and mediastinal lymph nodes are present in 5-10% of patients. • SVC syndrome • Pericarditis In 5% causing cardiac temponade in 40%

  10. PresentationChronic • occurs mostly in patients with underlying pulmonary disease • Reccurent histoplasmosis - latent in healed granulomas

  11. Chronic PresentationSymptoms/findings • cough, weight loss, fevers, and malaise. • ~ 90% of patients develop cavities that may enlarge and result in necrosis. • cavitations may cause hemoptysis, sputum production, and increasing dyspnea • formation of bronchopleural fistulae • Broncholiths • mediastinal granuloma and fibrosing mediastinitis

  12. Presentation Dessiminated Histoplasmosis • Occures in 1 out of 2000 acute cases but in patients with impaired cellular immunity it happens in 4-27% • Can present as subacute, acute or Hyperacute syndrome • typically involves • CNS • liver • spleen • rheumatologic • ocular • Lymphnodes • Mucosal ulcers in 50-60%

  13. Dessiminated HistoplasmosisSymptoms • Subacute/chronic form: constitutional symptoms and • GI: diarrhea and abdominal pain, abdominal mass or intestinal ulcers and lesions, Pancreatitis or cholecystitis • Cards: valvular disease, cardiac insufficiency, vegetations causing dyspnea, edema, angina, and fever. • CNS: headache, visual and gait disturbances, confusion, seizures, altered consciousness, and neck stiffness or pain (meningitis most common) • Other: Hypercalcemia, Mediastinal fibrosis

  14. Accute Dessiminated HistoplasmosisSymptoms • Acute form: generalized symptoms • Severe respiratory distress, DIC, Sepsis • organomegaly • CNS involvement (encephalopathy and meningitis) in 5-20% • Cutaneous lesions in10%

  15. Dessiminated HistoplasmosisOTHER • Ocular histoplasmosis syndrome • Macula involvement may result in blindness • 10% of patients have bilateral involvement • histo spots are Atrophic scars containing foci of lymphocytic cell infiltration

  16. Penumonia Aspergillosis Blasto Carcinoid Lymphoma Ulcerative colitis PCP Sarcoidosis Mycoplasma TB Lung Cancer Chlamedial Pneumonitis Differential diagnosis

  17. Diagnositc studies • Acute pulm • Sputum cult pos in 10-15% • Fungal Stain (sens 10%) • Complement-fixing Antibodies ( 1:8 exposure, 1:32 active dz) in 5-15% after 3 wks, 95% after 8wks • Anti-M antibody is detected in 50-80% • Anti-H antibody is detected in only 10-20% becomes undetectable in 6m • Serum and urine antigen (sens 25-75%) • Skin test becomes pos only after 1y • CXR: normal, LA, Patchy infiltrates (lower lung fields), reticular nodular or miliary pattern in severe cases

  18. Diagnositc studies • Chronic pulm • Mild anemia • Alk Phosph elevated • Sputum cult pos (sens 50-85%) • Fungal stain (sens 40%) • Complement-fixing Antibodies pos in 70-90% • Anti-M antibody in nearly 100% • Serum and urine antigen (sens 15%) • CXR: Histoplasmomas, Cavitations (upper lobes) in 90%, fibrotic scarring in long-standing cases.

  19. Diagnositc studies • Acute disseminated • Pancytopenia in 70-90% • Blood cult pos in 50-90% • Alk Phosph elevated • Anti-H antibody • Anti-M antibody • Serum and urine antigen (pos in 90%) • CXR hilar lymphadenopathy with diffuse nodular infiltrates in 50% of patients. • Subacute Disseminated • Pancytopenia rarely • Complement-fixing Antibodies pos • CXR has no acute findings • OTHER: PFT’s, Serum angiotensin converting enzyme concentrations , CT (adrenal insufficiency), Bronchoscopy, biopsy

  20. Treatment for symptomatic disease • No treatment for asymptomatic immunocompetent individuals • All chronic histo patients should be treated • Mild forms can be treated with Itraconazole or Ketoconazole PO for 3-6wks • Most cases may require 12-24m course • PO meds effective 75-85%, high relapse rates • Hospitalized Patients should be treated with amphoteracinB IV effective 59-100% given for total of 35 mg/kg • Small cavitary lesions can be monitored, lesions that persist or develop thick walls>3mm should be treated medically /surgically

  21. Treatment for Disseminated disease • Disseminated histo not requiring hospitalization, immunocompetant host - Itraconazole alone 6-18m • Severe dissemintated illness or failure of PO meds can be treated with amphoteracinB IV • Steroids can be used in disseminated histo with respiratory compromise in immunocompetant host (prednisone 60 qd for 2wks) • Patients with AIDS must be on life long therapy • weakly amphoteracinB IV effective 81-97% • Itroconazole effective 90% • Fluconazole effective 88% high relapse

  22. Outcome • Acute pulmonary has excellent prognosis, mediastinal LA resolves over months, rarely diffuse fibrosis occures • Chronic pulmonary Histo can cause cavities that may enlarge and result in necrosis. • Untreated cases may lead to progressive pulmonary fibrosis that results in respiratory and cardiac failure and recurrent infections. • Relapse • chronic pulmonary 20% • acute disseminated 50%, and decreases to 10-20% with life-long antifungal maintenance

  23. Outcome • subacute disseminated • death occurs within 2-24 months in untreated cases • 90% of cases resolve with treatment • Hospitalization frequently required • May be a problem for years with frequent relapse • acute Disseminated • death within weeks if untreated, 50% mortality despite treatment • Almost always requires hospitalization • DIC and sepsis are common • Approximately 5-10% of patients, treated or not, develop adrenal insufficiency • Approximately 10% of individuals develop hyperacute syndrome, which results in death.

  24. Outcome • Reinfection can occur

  25. Summary • Most prevalent endemic mycosis in US • Majority of cases asymptomatic • In immunocompromized host can become disseminated • Diagnostics include serologies, antigen, cultures, radiological findings • All chronic /disseminated cases should be treated • Treatment depends on severity • Great mimicker

  26. Reference • EMedicine • Histoplasmosis Author: Ryan C. Chang M.D. Consulting Staff, Department of Internal Medicine, Divisions of Pulmonary and Critical Care, Kaiser Permanente • UpToDate • Pathogenesis and clinical manifestations of disseminated histoplasmosis • Pathogenesis and clinical manifestations of disseminated histoplasmosis • Pathogenesis and clinical features of pulmonary histoplasmosis

More Related